Nasus Pharma Ltd (NSRX) Form 6-K — Sep 18, 2026
Nasus Pharma entered into an at-the-market sales agreement with BTIG, LLC on September 18, 2026, giving the clinical-stage drug developer the ability to sell up to $8,500,000 of ordinary shares from time to time at prevailing market prices on NYSE American. Sales will be made under the company's Form F-3 shelf registration (File No. 333-298693) declared effective September 11, 2026 and a prospectus supplement dated the same day as the agreement. BTIG, acting as sales agent, receives a commission of up to 3.0% of gross proceeds plus expense reimbursements capped at $75,000 at signing and $15,000 per fiscal period thereafter, and the company is under no obligation to sell any shares.
Key figures
- Gross Proceeds
- up to $8,500,000
- Trading venue
- NYSE American
- Atm max size usd
- $8,500,000
- Sales agent commission max
- 3.0%
- Btig expense reimbursement initial
- $75,000
- Btig expense reimbursement per period
- $15,000
- Registration statement effective date
- 2026-09-11
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.